KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Financing Activities (2016 - 2025)

CRISPR Therapeutics AG's Cash from Financing Activities history spans 11 years, with the latest figure at $116.4 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 589.82% year-over-year to $116.4 million; the TTM value through Dec 2025 reached $426.0 million, up 28.33%, while the annual FY2025 figure was $426.0 million, 28.33% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $116.4 million at CRISPR Therapeutics AG, down from $296.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $305.9 million in Q1 2024 and bottomed at -$466000.0 in Q2 2024.
  • The 5-year median for Cash from Financing Activities is $10.5 million (2022), against an average of $55.5 million.
  • The largest annual shift saw Cash from Financing Activities soared 19863.87% in 2021 before it crashed 102.78% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $6.3 million in 2021, then plummeted by 60.66% to $2.5 million in 2022, then soared by 1471.39% to $38.9 million in 2023, then plummeted by 56.66% to $16.9 million in 2024, then surged by 589.82% to $116.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Cash from Financing Activities are $116.4 million (Q4 2025), $296.8 million (Q3 2025), and $2.3 million (Q2 2025).